A clinical trials agenda for testing interventions in earlier stages of psychotic disorders.
A fundamental shift in the design of clinical trials for psychotic disorders is desirable and feasible. Priority should be placed on evaluation of the efficacy of interventions targeting different phases of illness. A range of traditional therapeutic approaches needs to be augmented by an increased emphasis on the potential benefits of informational, e-health, behavioural and neuroprotective strategies. A new national clinical trials platform, based on headspace, the National Youth Mental Health Foundation, is outlined. It provides the opportunity for conducting large multisite clinical trials in young people with emerging major mental disorders.
McGorry
Patrick D
PD
University of Melbourne, Melbourne, VIC. pmcgorry@unimelb.edu.au
Yung
Alison R
AR
Pantelis
Christos
C
Hickie
Ian B
IB
D014150:Antipsychotic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D011618:Psychotic Disorders / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D012107:Research Design; D018570:Risk Assessment
D014150:Antipsychotic Agents